Mirum Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary

Mirum Pharmaceuticals

05/08/2026 22:01

Mirum Pharmaceuticals, Inc. MIRM.OQ reported a quarterly adjusted loss of $1.06​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -12 cents.  The mean expectation of thirteen analysts for the quarter was for a loss of 68 cents per share. Wall Street expected results to range from -94 cents to -41 cents per share.
Revenue rose 37.9% to $176.24 million from a year ago; analysts expected $166.12 million. 
Mirum Pharmaceuticals, Inc.'s reported EPS for the quarter was a loss of $1.06​.
The company reported a quarterly loss of $67.23 million.
Mirum Pharmaceuticals, Inc. shares had fallen by 10.9% this quarter and gained 32.1% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 6.6% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy" 
Wall Street's median 12-month price target for Mirum Pharmaceuticals, Inc. is $145.00, about 28% above its last closing price of $104.33
This summary was machine generated from LSEG data August 5 at 09:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.68
-1.06
Missed
Mar. 31 2026 
-0.35
-1.08
Missed
Dec. 31 2025 
0.04
-0.10
Missed
Sep. 30 2025 
-0.16
0.05
Beat